Wedeh, G
Cerny-Reiterer, S
Eisenwort, G
Herrmann, H
Blatt, K
Hadzijusufovic, E
Sadovnik, I
Müllauer, L
Schwaab, J
Hoffmann, T
Bradner, J E
Radia, D
Sperr, W R
Hoermann, G
Reiter, A
Horny, H-P
Zuber, J
Arock, M
Valent, P
Article History
Received: 21 December 2014
Revised: 20 April 2015
Accepted: 21 April 2015
First Online: 9 June 2015
Competing interests
: JEB is a scientific founder of Tensha Therapeutics, which is developing drug-like derivatives of the JQ1 bromodomain inhibitor as cancer therapeutics, through a license from the Dana-Farber Cancer Institute. H-PH has a consultancy with and received honoraria from Novartis. PV has a consultancy with and received honoraria and research funding from Novartis. The authors declare no other conflict of interest.